Over 90 Total Lots Up For Auction at One Location - WA 04/08

Bay Labs announces new data that evaluates accuracy, efficiency and reproducibility of EchoGPS and AutoEF AI software

Press releases may be edited for formatting or style | March 14, 2019 Artificial Intelligence Health IT
SAN FRANCISCO--(BUSINESS WIRE)--Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, today announced the presentation of two studies assessing performance of the company’s deep learning software. The first evaluated the company’s software when used by medical professionals with no prior ultrasound experience to acquire diagnostic-quality echocardiograms, and the second evaluated the fully automated calculation of Ejection Fraction (EF) with accuracy and increased reproducibility. Results from these studies will be presented at the American College of Cardiology ACC.19 68th Annual Scientific Session.

Relevant ACC.19 presentations are scheduled this week in the Cutting Edge Echocardiography and Non-Invasive Imaging: Echo 1 sessions held in Poster Hall F:

“Innovative Ultrasound Technologies EchoGPS and AutoEF Help Novices Perform Efficient and Accurate Echocardiographic Monitoring in Cancer Patients” (March 16, Session 1128-355, 10–10:45 am) Presented by Alberta Yen, M.D., Division of Cardiovascular Medicine, Department of Medicine, Stanford University
stats
DOTmed text ad

Reveal Mobi Pro now available for sale in the US

Reveal Mobi Pro integrates the Reveal 35C detector with SpectralDR technology into a modern mobile X-ray solution. Mobi Pro allows for simultaneous acquisition of conventional & dual-energy images with a single exposure. Contact us for a demo at no cost.

stats
An ongoing prospective study conducted at Stanford University is assessing the use of deep learning software to aid in cardiac function monitoring in cancer patients undergoing treatment with potentially cardiotoxic therapies. Bay Labs’ EchoGPS™ and AutoEF software are being used in the study to aid in the acquisition of limited views of a standard echocardiogram by providing users with no prior ultrasound experience real-time guidance to obtain cardiac views, and to automatically calculate a left ventricular EF. Cardiac function monitoring for cardiotoxicity caused by cancer treatments is recommended for at-risk patients, however such screening remains underutilized. While these tools are not yet FDA cleared or approved for these purposes, the preliminary data assess these products for this potential future use.

Dr. Yen will present preliminary study results demonstrating a strong potential use of EchoGPS and AutoEF in a busy cancer clinic for cardiac function monitoring. To date, 37 patients have undergone echocardiograms performed by novices including oncologists and nurse practitioners in the oncology clinic with EchoGPS and minimal supervision, with 100 patients planned in this prospective study. The AutoEF software deemed 76% of the studies of sufficient quality to generate an EF measurement, and the root mean square deviation in EF was 4.8% between AutoEF and echocardiographers, suggesting that the AutoEF measurements may be accurate when calculated from studies gathered using EchoGPS.

You Must Be Logged In To Post A Comment